None of the review authors are employees of or have shares in a pharmaceutical company. Professors Vasudev and Young and Dr Macritchie have spoken at meetings and attended conferences sponsored by various pharmaceutical companies and have participated in trials sponsored by pharmaceutical companies. JRG currently receives research funding from the UK Medical Research Council, the UK Economic and Social Research Council, the National Institute for Health Research, and the Stanley Medical Research Institute. He was expert witness for Dr Reddy's Laboratories and is Chief Investigator on the CEQUEL trial to which GlaxoSmithKline have contributed and supplied investigational drugs and placebo. Dr Karine Macritchie has worked on a project supported by an award NS‐EU‐166 from the Translational Medicine Research Collaboration. This consortium comprises the Universities of Aberdeen, Dundee, Edinburgh and Glasgow, the four associated NHS Health Boards (Grampian, Tayside, Lothian and Greater Glasgow and Clyde), Scottish Enterprise and Pfizer (formerly Wyeth). She has also received funding for travel, accommodation and conference expenses from AstraZeneca. In the last two years Assistant Professor Vasudev has received financial remuneration for advice to Lundbeck.